The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Abstract
Purpose: The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor–positive, lymph node–negative breast cancer treated with adjuvant tamoxifen. The relationship between the RS and chemotherapy benefit is not known. Methods: The RS was measured in tumors from the tamoxifen-treated and tamoxifen plus chemotherapy–treated patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial. Cox proportional hazards models were utilized to test for interaction between chemotherapy treatment and the RS. Results: A total of 651 patients were assessable (227 randomly assigned to tamoxifen and 424 randomly assigned to tamoxifen plus chemotherapy). The test for interaction between chemotherapy treatment and RS was statistically significant (P = .038). Patients with high-RS (≥ 31) tumors (ie, high risk of recurrence) had a large benefit from chemotherapy (relative risk, 0.26; 95% CI, 0.13 to 0.53; absolute decrease in 10-year distant recurrence rate: mean, 27.6%; SE, 8.0%). Patients with low-RS (< 18) tumors derived minimal, if any, benefit from chemotherapy treatment (relative risk, 1.31; 95% CI, 0.46 to 3.78; absolute decrease in distant recurrence rate at 10 years: mean, −1.1%; SE, 2.2%). Patients with intermediate-RS tumors did not appear to have a large benefit, but the uncertainty in the estimate can not exclude a clinically important benefit. Conclusion: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor–positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
Gene expression profiles of human breast cancer progression
Ma, X.-J., Salunga, R., Tuggle, J. T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker, K., Zhang, B. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931261100 · Cited by 887
Cited by
Items 101–111 of 111
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Straver, M. E., Glas, A. M., Hannemann, J., Wesseling, J., van de Vijver, M. J., Rutgers, E. J. T., Vrancken Peeters, M.-J. T. F. D., van Tinteren, H., van‘t Veer, L. J., & Rodenhuis, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0333-1 · Cited by 252
Eustace, A., Mani, N., Span, P. N., Irlam, J. J., Taylor, J., Betts, G. N. J., Denley, H., Miller, C. J., Homer, J. J., Rojas, A. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0542 · Cited by 240
“Multi-gene tests are already available in outpatient settings for breast (32-36) and colon (37) cancer.”
Cheong, J.-H., Yang, H.-K., Kim, H., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y.-K., Kim, H.-H., Lee, H. S., Lee, K. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30108-6 · Cited by 219
Self-citationDavatzikos, C., Rathore, S., Bakas, S., Pati, S., Bergman, M., Kalarot, R., Sridharan, P., Gastounioti, A., Jahani, N., Cohen, E., et al. (2018) · Journal of Medical Imaging · doi:10.1117/1.jmi.5.1.011018 · Cited by 204
“25,58 All women had their primary tumor tested with Oncotype DX, 59 an assay that measures RNA expression of 21 genes from formalin-fixed paraffin-embedded tissue and provides a score recurrence risk 10 years after treatment ( low ≤ 17% , 18% medium 30% , high ≥ 31% ).”
MethodKennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., Whiteaker, J. R., Lin, C., Kim, J. S., Zhang, Y., Wang, X., Ivey, R. G., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2763 · Cited by 184
Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
Jenkins, E. O., Deal, A. M., Anders, C. K., Prat, A., Perou, C. M., Carey, L. A., & Muss, H. B. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0184 · Cited by 165
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre, F., & Pusztai, L. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0636 · Cited by 134
“A recent report examined the value of the recurrence score for predicting benefit from adjuvant CMF chemotherapy in 651 patients with ER-positive, node-negative breast cancer included in the NSABP B20 randomized study”
Barriers to the Use of Personalized Medicine in Breast Cancer
Weldon, C. B., Trosman, J. R., Gradishar, W. J., Benson, A. B., & Schink, J. C. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000448 · Cited by 76
Association of sleep duration and breast cancer OncotypeDX recurrence score
Thompson, C. L., & Li, L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2144-z · Cited by 58
“chemotherapy [7].”
Bombard, Y., Rozmovits, L., Trudeau, M., Leighl, N. B., Deal, K., & Marshall, D. A. (2014) · Current Oncology · doi:10.3747/co.21.1782 · Cited by 30
Mondol, R. K., Millar, E. K. A., Sowmya, A., & Meijering, E. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3418341 · Cited by 29
Metadata
- Authors
- Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., Costantino, J. P., Geyer, C. E., Wickerham, D. L., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-08-10
- Volume
- 24
- Issue
- 23
- Pages
- 3726-3734
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160377567
- Cited by
- 2,579
- References
- 24
- FWCI
- 45.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.